-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Proton pump inhibitors (PPIs) long-term inhibit basal and food-stimulated gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase (or proton pump) of gastric parietal cells
Digestion
Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.
diabetes
Researchers conducted a case-control study in Lombardy, Italy, of 777,420 patients newly treated with PPIs between 2010 and 2015
The incidence of diabetes was 19% (95% CI 15-24) in patients who used PPIs for 8 weeks to 6 months, 6 months to 2 years, and >2 years compared with those who used PPIs for <8 weeks.
CONCLUSIONS: Regular and long-term use of PPIs is associated with a higher risk of diabetes
Regular and long-term use of PPIs is associated with a higher risk of diabetes
Original source:
Stefano Ciardullo, et al.
Prolonged use of proton pump inhibitors and risk of type 2 diabetes: results from a large population-based nested case-control
study